MOLECULAR DIAGNOSTICS RESEARCH & DEVELOPMENT: cost and payments to doctors
What Medicare Part D paid pharmacies for MOLECULAR DIAGNOSTICS RESEARCH & DEVELOPMENT, and the payments that named it as the associated device or medical supply under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Roche Molecular Systems, Inc.?
Roche Molecular Systems, Inc. reported the most payments naming MOLECULAR DIAGNOSTICS RESEARCH & DEVELOPMENT. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $279K
- Providers
- 35
- Transactions
- 70
- Average per transaction
- $3,992
The per-transaction average — $3,992 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 35 providers the average total is $7,983, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Roche Molecular Systems, Inc. | $279,416 | 100.0% |
Other products from Roche Molecular Systems, Inc.
The company that reported the most payments naming MOLECULAR DIAGNOSTICS RESEARCH & DEVELOPMENT also reports against these.
- COBAS INSTRUMENTS & REAGENTS$766,477
- DIAGNOSTICS INFORMATION SYSTEMS$652,616
- cobas Influenza A/B Nucleic acid test for use on the cobas Liat System$56,370
- CINtec PLUS Cytology$30,001
- cobas 4800 CT/NG Test v2.0$18,000
- cobas 6800 System$6,653
- cobas#x00AE EBV$353
- AVENIO Millisect$274
- BenchMark ULTRA$267